NMN Results Timeline: What Studies Measured, and When

Questions about "how long NMN takes" assume the literature tracks a felt experience over time. It does not. Published trials define a fixed supplementation period, choose a small number of endpoints, and measure those endpoints at scheduled visits — often only at baseline and at the end of the study. This page maps those measurement windows: which populations were studied, how long the study periods ran, and what was assessed at each point. This page is for educational purposes only and is not medical advice; consult a licensed physician before considering any compound.

Why a "timeline" in the literature is really a schedule of measurements

A trial timeline reflects the researchers' design choices, not a biological countdown. A 2023 review of human clinical trials of nicotinamide mononucleotide examined safety and antiaging-related outcomes across the published studies and described the field as still comparatively young, with heterogeneous designs and endpoints (PMID 37619764). A 2025 review of the biological properties, synthetic pathways and proposed anti-aging mechanisms of NMN similarly framed several mechanistic claims as open research questions rather than settled findings (PMID 40550930). Those two roll-ups matter for timeline reading: when a study reports a change "at 60 days," that is the point at which a measurement happened to be taken, not evidence that the change first appeared on that day.

Human trials: populations, durations and measured endpoints

The short end: weeks-scale safety evaluations

The shortest human datasets are safety-oriented. Researchers reported a safety evaluation of oral β-nicotinamide mononucleotide administration in healthy adult men and women, with clinical assessment of the administration period rather than performance or aging endpoints (PMID 36002548). Studies of this shape are designed to detect tolerability problems within a short observation window; they are not structured to detect slow-moving physiological change, and the 2023 clinical-trial review noted that safety-focused designs make up a meaningful share of the human literature (PMID 37619764).

Around two months: the 60-day randomized trial

One of the more frequently discussed human datasets is a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent trial in healthy middle-aged adults that ran for 60 days and reported increases in blood NAD concentrations in the NMN groups compared with placebo (PMID 36482258). The same trial measured six-minute walking distance and a blood biological age index over that 60-day window, and the researchers described the design as dose-dependent across the assigned groups (PMID 36482258). For timeline purposes, the salient detail is that the trial's endpoint schedule ended at day 60 — nothing in that study speaks to what happens at day 120 or day 365.

Ten weeks: an insulin-sensitivity endpoint

A 2021 trial in Science administered NMN at 250 mg per day for 10 weeks to prediabetic postmenopausal women with overweight or obesity and reported increased muscle insulin sensitivity assessed by hyperinsulinemic–euglycemic clamp (PMID 33888596). The same study reported no differences between groups in other measures it assessed, including body composition and blood pressure (PMID 33888596). This is a useful illustration of how narrow an endpoint can be: the clamp procedure was performed at the end of the 10-week period, so the study describes a between-group difference at one timepoint in one tissue-level measure, in one specific population.

Longer supplementation: metabolism, sleep and NAD biosynthesis

A 2024 study in Endocrine Journal examined long-term nicotinamide mononucleotide supplementation in healthy, middle-aged Japanese men and reported on safety alongside metabolic parameters, sleep measures and NAD biosynthesis (PMID 38191197). Sleep is one of the few subjective domains that has been formally measured in this literature; where it appears, it was captured through structured assessment at study visits rather than through open-ended self-report, and the researchers reported it alongside biochemical measures of NAD biosynthesis (PMID 38191197).

What preclinical timelines showed (animal and cell models — clearly labeled)

Because human time-course data is limited, much of what is written about "when NMN does things" traces back to animal or cell work. These models permit tissue sampling that human trials cannot, but their timelines do not transfer to people.

• Cardiac function in a knockout model. Researchers reported that NMN improved cardiac function in SIRT3 knockout mice and attributed the effect to the SIRT1/PGC-1α pathway (PMID 40775529).
• Ovarian reserve in a premature ovarian insufficiency model. A 2024 study reported that NMN improved the ovarian reserve of premature ovarian insufficiency by inhibiting NLRP3-mediated pyroptosis of ovarian granulosa cells (PMID 39593096).
• Fertility during chemotherapy. A 2024 report in EMBO Molecular Medicine described fertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome (PMID 39169162).
• Neurodegeneration and gut barrier in an induced-aging model. Researchers reported that NMN reversed D-galactose-induced neurodegeneration and enhanced the intestinal barrier of mice by activating the Sirt1 pathway (PMID 40276601).
• NAD metabolism in reproductive immunology. A 2025 study reported that NAD+ metabolism maintains the homeostasis of decidual macrophages in early pregnancy (PMID 40471104).

These are mechanism-oriented models with induced pathology, genetic knockouts or chemotherapy exposure. None of them were designed to describe a timeline in healthy humans, and the 2025 mechanisms review explicitly listed translation from such models as one of the field's outstanding challenges (PMID 40550930).

The NAD field is not only about raising NAD

A detail that rarely appears in popular timeline discussions: parts of the NAD literature pursue the opposite direction. A 2026 paper described GD2-directed NAMPT inhibition using antibody–drug conjugates in neuroblastoma, targeting NAD salvage rather than augmenting it (PMID 41707282). That work is unrelated to supplementation timelines, but it shows that NAD-pathway manipulation is studied as a context-dependent intervention rather than a uniformly beneficial one.

Where the human timeline evidence is thin

Several limitations are worth stating plainly, and the published reviews state them too.

1. Few intermediate timepoints. Most reported outcomes come from end-of-study visits; the 60-day randomized trial and the 10-week insulin-sensitivity trial both anchor their key findings to scheduled assessments rather than to continuous tracking (PMID 36482258, PMID 33888596).
2. Short total durations. The 2023 update on safety and antiaging effects in human clinical trials characterised the available trials as limited in scale and duration relative to the claims made about the compound (PMID 37619764).
3. Population specificity. The insulin-sensitivity result was reported in prediabetic postmenopausal women with overweight or obesity, not in general adults (PMID 33888596), while the 60-day trial enrolled healthy middle-aged adults (PMID 36482258).
4. Biomarker versus outcome. A rise in blood NAD concentration is a biochemical measurement, and the 60-day trial reported it as such alongside separate functional endpoints (PMID 36482258); the 2025 review cautioned that mechanistic pathways linking NAD levels to aging outcomes remain under investigation (PMID 40550930).

Adverse Events Across Timepoints: What Studies Report

Safety monitoring in these trials followed the same visit schedule as efficacy measurement. A 2022 safety evaluation of oral β-nicotinamide mononucleotide administration in healthy adult men and women reported on tolerability across the administration period (PMID 36002548). The 2024 study in healthy, middle-aged Japanese men reported safety outcomes alongside its metabolic, sleep and NAD biosynthesis measures over long-term supplementation (PMID 38191197). The 2023 review across human clinical trials summarised the reported safety picture from the trials available at that time and noted the limited duration of follow-up as a constraint on conclusions (PMID 37619764). Because follow-up in these designs generally ended when the supplementation period ended, the literature does not describe what longer-horizon monitoring would show.

How to read a timeline claim critically

When a timeline statement appears anywhere, three questions locate it in the evidence. First, which measurement produced it — a blood NAD assay, a clamp study, a walk test, or a questionnaire? The 60-day randomized trial used several of these in parallel and reported them separately (PMID 36482258). Second, in whom — the 10-week trial's population was narrowly defined (PMID 33888596). Third, was it human or animal work — the cardiac, ovarian, neurological and pregnancy findings described above came from animal and cell models (PMID 40775529, PMID 39593096, PMID 40276601, PMID 40471104). A timeline that cannot answer those three questions is an extrapolation, not a finding.

Related reading

For background on what NMN is, how it sits in NAD metabolism, and the broader evidence base, see the NMN overview.

References

• The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update (Advances in Nutrition, 2023)
• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (GeroScience, 2023)
• Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (Science, 2021)
• Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men (Endocrine Journal, 2024)
• Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women (Scientific Reports, 2022)
• Biological properties, synthetic pathways and anti-aging mechanisms of nicotinamide mononucleotide (NMN): Research progress and challenges (Biogerontology, 2025)
• NMN improves cardiac function in SIRT3 knockout mice via the SIRT1/PGC-1α pathway (Scientific Reports, 2025)
• Nicotinamide mononucleotide improves the ovarian reserve of POI by inhibiting NLRP3-mediated pyroptosis of ovarian granulosa cells (Journal of Ovarian Research, 2024)
• Fertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome (EMBO Molecular Medicine, 2024)
• NMN reverses D-galactose-induced neurodegeneration and enhances the intestinal barrier of mice by activating the Sirt1 pathway (Frontiers in Pharmacology, 2025)
• NAD+ Metabolism Maintains the Homeostasis of Decidual Macrophages in Early Pregnancy (FASEB Journal, 2025)
• GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma (European Journal of Medicinal Chemistry, 2026)